Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and iron sucrose, offer improved safety profiles and more efficient iron delivery compared with older compounds, thanks to their more stable carbohydrate shells and controlled iron release mechanisms.
Video content above is prompted by the following:
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing
September 4th 2025Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).
Read More